Baxter price target lowered to $42 from $45 at Evercore ISI

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter (BAX) to $42 from $45 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.